Head-to-head comparison
| Property | BPC-157 | Ipamorelin |
|---|---|---|
| Category | Recovery | Muscle & Growth |
| Legal Status | Reclassification Pending | Reclassification Pending |
| Primary Route | subcutaneous | subcutaneous |
| Half-life | ~4 hours (estimated) | ~2 hours |
| Mol. Weight | 1,419.53 Da | 711.85 Da |
| Side Effects | Nausea (rare), Dizziness, Headache | Headache, Flushing, Injection site pain |
Key differences
- Primary purpose: BPC-157 is a tissue repair peptide for injury recovery (tendons, ligaments, gut); ipamorelin is a GH secretagogue for growth hormone optimization.
- Mechanism: BPC-157 activates the FAK-paxillin pathway for tissue healing and modulates nitric oxide; ipamorelin selectively activates ghrelin receptors to stimulate pituitary GH release.
- Dosing schedule: BPC-157 is typically dosed twice daily at 250–500 mcg; ipamorelin is typically dosed 2–3 times daily at 200–300 mcg, often paired with CJC-1295.
- Duration of use: BPC-157 is commonly used in 4–8 week cycles aligned with injury recovery; ipamorelin is used in longer cycles for sustained GH optimization.
- Evidence type: BPC-157 has over 100 preclinical studies on tissue repair; ipamorelin has Phase II clinical data and preclinical GH studies.
- Hormonal effects: Ipamorelin stimulates GH release and elevates IGF-1; BPC-157 does not directly affect the GH/IGF-1 axis.
- FDA status: Neither is FDA-approved. BPC-157 is under FDA reclassification review; ipamorelin remains a research compound.
The verdict
BPC-157 and ipamorelin serve non-overlapping purposes and are frequently discussed as complementary rather than competing peptides. BPC-157 is for active injury recovery — use it when something is hurt. Ipamorelin is for GH optimization — use it for anti-aging, body composition, and general recovery enhancement. Many protocols combine both: ipamorelin for systemic GH support and BPC-157 for targeted tissue repair.
Frequently asked questions
They work through entirely different mechanisms (tissue repair vs GH secretion) and are commonly combined in recovery-focused protocols. BPC-157 provides direct tissue healing while ipamorelin's GH elevation supports systemic recovery. No clinical studies have evaluated this combination, but the mechanisms do not conflict.
For direct injury recovery (tendon, ligament, gut healing), BPC-157 is the more targeted option with over 100 preclinical studies on tissue repair. Ipamorelin supports recovery indirectly through growth hormone elevation, which enhances overall tissue regeneration and repair capacity. Both can contribute to recovery through different mechanisms.
Ipamorelin does not directly target tissue repair the way BPC-157 does. However, the growth hormone it stimulates contributes to tissue regeneration, collagen synthesis, and overall recovery. GH elevation is a systemic support mechanism, not a targeted repair pathway.
If you have an active injury or tissue damage, BPC-157's direct repair mechanism is more immediately relevant. If your goal is general anti-aging, body composition improvement, or GH optimization without a specific injury, ipamorelin is more applicable. Many protocols use both simultaneously.
Neither is FDA-approved for human use. BPC-157 is under FDA reclassification review as part of the 14-peptide initiative. Ipamorelin remains a research compound. Both are available from research suppliers. Legal status should be verified as the regulatory landscape continues to evolve.